מדיקינט MR כמוסות בשחרור מושהה 40 מ"ג ישראל - עברית - Ministry of Health

מדיקינט mr כמוסות בשחרור מושהה 40 מ"ג

mediline ltd. - methylphenidate hydrochloride 40 mg - modified release capsules - methylphenidate - medikinet modified release capsules are indicated as part of a comprehensive treatment program for attention-deficit/hyperactivity disorder (adhd) in children over 6 years of age when remedial measures alone prove insufficient. treatment must be under the supervision of a specialist in childhood behavioural disorders. diagnosis should be made according to dsm-iv criteria or the guidelines in icd-10.

ריטלין ® LA כמוסות בשחרור מושהה 10 מ"ג ישראל - עברית - Ministry of Health

ריטלין ® la כמוסות בשחרור מושהה 10 מ"ג

novartis pharma services ag - methylphenidate hydrochloride 10 mg - modified release capsules - methylphenidate - attention deficit hyperactivity disorder (adhd) .

רדיאן B מאסז' ישראל - עברית - Ministry of Health

רדיאן b מאסז'

devries & co. ltd - camphor; capsicum oleoresin; menthol; methyl salicylate - קרם - menthol 2.54 %w/w; camphor 1.43 %w/w; capsicum oleoresin 0.005 %w/w; methyl salicylate 0.42 %w/w - preparations with salicylic acid derivatives - relief of rheumatic pains and mild muscle pains.

רדיאן בי ספריי ישראל - עברית - Ministry of Health

רדיאן בי ספריי

devries & co. ltd - acetylsalicylic acid; camphor; menthol; methyl salicylate - ספריי - menthol 1.4 %; acetylsalicylic acid 1.2 %; camphor 0.6 %; methyl salicylate 0.6 % - preparations with salicylic acid derivatives - relief of light muscular and rheumatic pains.

Abbott FreeGo Enteral Feeding Pump ישראל - עברית - Ministry of Health

abbott freego enteral feeding pump

אבוט מעבדות רפואיות בע"מ באמצעות פרומדיקו בע"מ - אחות - enteral tube feeding is a method of providing nutrition to patients whose nutrition needs cannot be met by oral intake alone, for variety of clinical reasons. enteral feeding may be indicated for patients: who have difficulty chewing or swallowing, e.g. sroke, post-operative patients; with loss appetite due to chronic illness, e.g. cancer, hiv; with increased nutritional needs, e.g. wound healing, trauma/injury; with gastrointestinal disease, e.g. cancers of gi tract.

טוביאז 4 מג ישראל - עברית - Ministry of Health

טוביאז 4 מג

pfizer pharmaceuticals israel ltd - fesoterodine fumarate - טבליות עם שחרור מושהה - fesoterodine fumarate 4 mg - fesoterodine - fesoterodine - treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur in patients with overactive bladder syndrome.

טוביאז 8 מג ישראל - עברית - Ministry of Health

טוביאז 8 מג

pfizer pharmaceuticals israel ltd - fesoterodine fumarate - טבליות עם שחרור מושהה - fesoterodine fumarate 8 mg - fesoterodine - fesoterodine - treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur in patients with overactive bladder syndrome.

נאוסטיגמין - המלן 2.5 מג מל זריקה ישראל - עברית - Ministry of Health

נאוסטיגמין - המלן 2.5 מג מל זריקה

pharma medis - neostigmine methylsulfate - תמיסה להזרקה - neostigmine methylsulfate 2.5 mg/ml - neostigmine

קלופידול פלוס וטרינרי ישראל - עברית - Ministry of Health

קלופידול פלוס וטרינרי

phibro animal health ltd., israel - clopidol; methyl benzoquate - אבקה מסיסה - clopidol 20 %; methyl benzoquate 1.66 % - for prevention of eimeria susceptible to clopidol and methylbenzoquate in broilers.

ארומזין ישראל - עברית - Ministry of Health

ארומזין

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.